Otherwise numerous CCK2 agonists, including Boc– CCK-4, BC197 (Derrien et al. 1994; Ladurelle et al. 1997) and compound 1 (Boc-Trp-NMeNle-Asp-Phe-NH2, I. Léna, personal communication), exert a “CCK2A” pharmacological profile, essentially characterised by anxiogenic properties.